NASDAQ · Biotechnology

MGX (MGX) Stock

$1.22 +0.83% NASDAQ: MGX Healthcare

Valuation

MetricValue
Price$1.22
Market Cap$45.93M
P/E Ratio-0.84
P/B Ratio0.34
P/S Ratio2.07
EPS (TTM)$-1.68
52-Week High$3.95
52-Week Low$1.13
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.02%
ROA-23.44%
ROCE-60.76%
Gross Margin-12.54%
Operating Margin-4.15%
Net Margin-3.85%
Debt/Equity0.28
Current Ratio7.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$17.0M$45.0M$52.0M$25.0M
Operating Profit$-24.0M$-45.0M$-78.0M$-89.0M$-96.0M
Net Profit$-21.0M$-44.0M$-68.0M$-78.0M$-88.0M
EPS$-3.62$-1.16$-1.82$-2.09$-2.36
Op Margin-9854.7%-259.5%-175.4%-170.0%-380.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$142.0M$414.0M$365.0M$325.0M$221.0M
Total Liabilities$175.0M$489.0M$150.0M$90.0M$63.0M
Cash$39.0M$184.0M$141.0M$27.0M$42.0M
Borrowings$49.0M$19.0M$48.0M$46.0M$41.0M

Latest News

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio GlobeNewswire · Jul 15, 2026 Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026 Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St. · May 14, 2026 Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates Zacks · May 12, 2026 Metagenomi Therapeutics: Q1 Earnings Snapshot Associated Press · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$24.0M$30.0M$-91.0M$-109.0M$-89.0M
Investing Cash Flow$-77.0M$-136.0M$36.0M$-91.0M$103.0M
Financing Cash Flow$0$0$-3.0M$0$-1.0M
Net Cash Flow$-10.0M$147.0M$-45.0M$-113.0M$14.0M
Free Cash Flow$21.0M$16.0M$-101.0M$-112.0M$-89.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.64
FCF Yield-189.81%
Quick Ratio6.43
Interest Coverage—
Return 1Y-37.02%
Return 3Y—
Return 5Y—

Ownership

Insiders Held18.97%
Institutions Held19.51%
Institutions Float Held24.08%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,057,9442026-03-31
Renaissance Technologies, LLC787,9002026-03-31
Catalio Capital Management, LP 528,9932026-03-31
Peapod Lane Capital LLC 516,7612026-03-31
Two Sigma Investments, LP496,7672026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%

About MGX

MGX is led by CEO Jian Irish, employs 202 people, headquartered in US, publicly traded since 2006.

MGX stock trades at $1.22 with a market capitalization of $45.93M. The stock is valued at a price-to-earnings (P/E) ratio of -0.84, price-to-book of 0.34, price-to-sales of 2.07. Over the past 52 weeks the stock has ranged between $1.13 and $3.95, and currently trades 69.1% below its 52-week high.

On profitability, MGX generates a return on equity (ROE) of -49.02%, return on capital employed of -60.76%, an operating margin of -4.15%, a net profit margin of -3.85%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides